FindTrial
Sign In

A novel inflammatory marker to find out the association of inflammation in the patients diagnosed with fibromyalgia.

A single-centric, assessor-blinded observational non-inferiority study to elicit the association of systemic immune inflammation index(SII) in patients diagnosed with fibromyalgia - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/03/063418
Enrollment
156
Registered
2024-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M797- Fibromyalgia

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patient diagnosed with fibromyalgia not under treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
All demographic data among both the group will be noted .Hemoglobin, neutrophil, lymphocyte, monocyte, and platelet counts, MPV, NLR, PLR, MLR, and SII will be analyzed. SII will be calculated by multiplying the NLR and the platelet count.Timepoint: at the time of first visit to clinic—

Secondary

MeasureTime frame
: The disease activity and the level of depression in relation to SII score will be recorded using Fibromyalgia Impact Questionnaire (FIQ) and PHQ9 rating scale respectively prior to initiation of any treatment.Timepoint: at the time of first visit to clinic—

Countries

India

Contacts

Public ContactGautam Das

Daradia the pain clinic

gdas2310@gmail.com9163357246

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026